BPC 157 compounding gets a pharmacy path while human proof stays thin

BPC 157, the recovery peptide sold as one half of the so-called Wolverine shot, now has a federal path into US pharmacies. Under a Department of Health and Human Services policy issued on October 28, 2026, BPC 157 compounding by licensed pharmacies will not draw federal enforcement when strict conditions are met. The shift, examined in a Business Insider feature this week, could move some users away from unregulated online sellers. It does not make the peptide an approved drug, and the first controlled trial in patients is small and not due to start until 2027.

What the HHS enforcement discretion policy allows

The HHS enforcement discretion policy that opens the door to BPC 157 compounding names six peptides: BPC 157, TB-500, Epitalon, KPV, MOTS-c and Semax. According to a BakerHostetler client alert, HHS said licensed physicians, federal facilities and state-licensed pharmacies that make products from these substances will not face federal action while the FDA works on rulemaking for the 503A bulks list. The bar is high. The raw peptide must come from an FDA-registered maker that follows good manufacturing practice and supplies a valid certificate of analysis. Each product needs a patient-specific prescription and may hold only one listed peptide, so a single compounded product cannot mix BPC 157 with TB-500. Labels must state that the drug is compounded and not for resale.

The limits matter as much as the permission. The policy only reaches 503A pharmacies and physicians; it leaves out 503B outsourcing facilities, the larger plants that make drugs in volume, and it gives no cover to anything marketed as a research chemical or a dietary supplement. The National Law Review reported that the policy neither adds the six peptides to the 503A bulks list nor amounts to FDA approval. HHS presented it as a way to steer people away from imported research-use-only peptides that it said pose a safety risk. Serious side effects must be reported to FDA MedWatch and state authorities. The notice was due for Federal Register publication on October 30, with comments open for two weeks after that, BakerHostetler said, and HHS may revise or withdraw it.

Why the Wolverine shot drew federal attention

BPC stands for body protection compound. Business Insider reports that Croatian scientist Predrag Sikiric first isolated it from human gastric juice in the 1990s, and that animal studies suggest it may speed tissue repair. Users swallow it or inject it, and in the Wolverine shot it is paired with TB-500 and marketed for tendon and ligament injuries. The feature traces its rise through gym and biohacking circles, fed by social media and by sellers outside the regulated system. Dr. Jesse Morse, a Florida physician who practices family and sports medicine, said he has taken it himself and given it to patients since about 2020. He called it a "beautiful peptide" for injuries and pain, a view that rests on experience rather than controlled human trials.

Even with the new policy, compounded BPC 157 remains an unapproved drug whose safety and benefit in people have not been shown in a controlled trial.

Federal attention changed the access picture quickly. AJMC reported that in July an FDA advisory committee voted to recommend BPC 157, KPV and TB-500 for the 503A bulks list, going against career FDA staff scientists, who had opposed all seven peptides under review. HHS then acted before any final rule with its interim policy. For a patient, the practical shift is from an anonymous website to a prescriber and a licensed pharmacy that must document where the raw powder came from. Even with the new policy, compounded BPC 157 remains an unapproved drug whose safety and benefit in people have not been shown in a controlled trial. Our earlier report on the HHS peptide compounding policy sets out the objections from FDA scientists in more detail.

Gray market peptides keep the biggest risks

Because BPC 157 is not FDA approved, most users still get it from online sellers, Business Insider reports, and gray market peptides can be contaminated, wrongly dosed or entirely fake. "The market is ahead of the research, which is a little frightening," said Dr. Shiloah Kviatkovsky, who teaches orthopedic surgery at an Arkansas medical school and will lead the planned trial. The cofounder of a peptide review forum told the outlet that some sellers fake quality certificates. Crackdowns on the largest vendors have led dozens of smaller ones to take their place, and reporters even found BPC 157 on sale in a Brooklyn bodega. Morse said the clearest warning sign is a product labelled "not for human use," and he advised against buying from such sellers at all.

One Denver user told Business Insider that his wife developed chills, fever, nausea and diarrhea after taking BPC 157. He linked the illness to endotoxins, bacterial toxins that can contaminate peptides, and said she recovered after she stopped. Some doctors also worry, in theory, that a peptide which helps new blood vessels form might help tumors grow, although the feature notes that no study has tied it to cancer in practice. The HHS policy speaks to sourcing, since pharmacies must use registered makers and tested material, but it cannot answer the clinical questions. Harm from unregulated products is also being counted abroad, where NSW emergency department visits tied to unapproved peptides have climbed over the past year.

A BPC 157 clinical trial is planned for 2027

The first controlled test in patients will be small. A BPC 157 clinical trial set to begin in summer 2027 will track 20 people after shoulder surgery to see whether the peptide speeds healing and whether it causes side effects. Patients will be randomly assigned, and neither they nor the doctors will know who gets the peptide or a placebo. Kviatkovsky told Business Insider the study is only a first step toward judging safety and effectiveness in people. Co-investigator Dr. J. Ryan Hill, an orthopedic surgeon at the same university, said the team will set blood tests and MRI scans against objective scores for pain and function. He said active patients, mostly between 20 and 40 years old, already ask him whether it helps and whether it is safe.

For access, the picture is uneven. The policy summaries we reviewed set no price and say nothing about insurance, so cost and coverage for compounded peptides remain open questions. Patients will also need a prescriber willing to write for an unapproved drug and a pharmacy able to meet every sourcing and testing condition. Ingredient supply is unsettled too: Celularity and Vesalius have announced plans to serve compounding pharmacies but named no start date. Morse said he hopes the FDA will eventually give these treatments legitimacy, so patients have safer choices. "Peptides are out of the bag," he said. Until trial results arrive, BPC 157 compounding offers a more traceable source, not evidence that the peptide works.

Conclusion

BPC 157 compounding now has federal room to operate through licensed 503A pharmacies, under ten conditions on sourcing, labelling and reporting. That gives patients a prescription route with traceable ingredients and an alternative to gray market sellers. It does not approve the drug, cover 503B plants or show whether BPC 157 heals injuries in people. The 20 patient trial planned for 2027 is the next real data point, and HHS can change the policy at any time. This story is for information only and is not medical advice.